Lonza has agreed to divest its Capsules and Health Ingredients business to Lone Star Funds for an enterprise value of CHF 2.3 billion at closing, with the deal expected to close in the second half of 2026. Lonza expects upfront cash proceeds of CHF 1.7 billion and will retain a 40% stake in the business, with additional preferential participation in a future exit; total undiscounted proceeds at full exit are expected to be at or above CHF 3 billion. Lonza also said it has signed agreements to divest its Personalized Medicines business, the MODA software platform and a small-molecules micronization site in Monteggio, Switzerland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lonza Group Ltd. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: adhoc_2287370_en), on March 06, 2026, and is solely responsible for the information contained therein.